Kirkland's Daniel Wolf on uniqueness of Bristol-Myers-Inhibitex

Kirkland's' Daniel Wolf tells The Deal Pipeline about his unique experience in advising Bristol-Myers Squibb in its $2.5 billion acquisition of Inhibitex.

More episodes of The Deal TV

Featured episodes in News & Politics

The Deal TV

Inside The Deal brings you the latest on business, the economy, mergers and acquisitions and dealmaking.